Overview
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Description
This is a single arm, prospective, multicenter post-approval study.
Eligibility
Inclusion Criteria:
- Native or surgically-repaired RVOT with severe PR
- Clinically indicated for pulmonary valve replacement
- Planned for treatment with the Alterra prestent and SAPIEN 3 THV
Exclusion Criteria:
- Inability to tolerate an anticoagulation/antiplatelet regimen
- Active bacterial endocarditis or other active infections